Archives
-
E-4031: hERG Blocker in Cardiac Research
2026-10-03
E-4031 is a hERG potassium channel blocker used in cardiac electrophysiology research to study IKr inhibition, QT interval prolongation, and repolarization instability. Its reported effects support mechanistic and proarrhythmic substrate modeling, but they do not establish clinical efficacy or predict torsades de pointes (TdP) in every biological system.
-
Cross-Kingdom Promoters in E. coli and Yeast
2026-10-02
The reference study introduces modular hybrid promoters that combine bacterial and yeast transcriptional and translation-initiation elements to support tunable gene expression in Escherichia coli and Saccharomyces cerevisiae. The resulting architecture preserved relative expression strength across both hosts and enabled coordinated prodeoxyviolacein biosynthesis, providing a practical foundation for more portable synthetic-biology constructs.
-
NADH Workflows for Redox Research
2026-10-01
Build more interpretable redox experiments with NADH, from controlled cell exposures to mitochondrial and photocatalytic assays. This guide connects practical handling, quantitative controls, and the Sirt6-centered findings of an osteoporosis study without overstating what the evidence proves.
-
AICAR for AMPK-Driven Inflammation Research
2026-10-01
Discover how AICAR converts AMPK biology into practical workflows for macrophage inflammation, energy metabolism, and cellular stress studies. This guide combines reference-backed pathway logic with product-aligned dosing, controls, and troubleshooting for more reproducible assays.
-
TCAIM–OGDH Control of Mitochondrial Metabolism
2026-09-30
The reference study identifies TCAIM as a mitochondrial DNAJC co-chaperone that specifically binds native OGDH and promotes its reduction through HSPA9 and LONP1. This mechanism links mitochondrial proteostasis to OGDH complex activity and carbohydrate catabolism, offering a framework for interpreting post-translational control in cellular metabolism research.
-
Ranolazine: Mechanism and Research Workflow
2026-09-30
Ranolazine is an anti-ischemic agent used in research on late sodium current inhibition, myocardial relaxation, and metabolic remodeling. This article links its product specifications to cardiac ischemia research while defining storage, formulation, interpretation, and cross-domain limits.
-
5-(N,N-dimethyl)-Amiloride Assay Guide
2026-09-29
This scenario-based guide explains how 5-(N,N-dimethyl)-Amiloride (hydrochloride), SKU C3505, can help researchers dissect Na+/H+ exchanger signaling while avoiding common viability-assay confounders. It covers mechanism, handling, controls, data interpretation, and practical supplier-selection criteria for endothelial, cardiac, and cytotoxicity workflows.
-
Separating Growth Inhibition from Cancer Cell Death
2026-09-29
Hannah R. Schwartz’s dissertation shows why relative viability and fractional viability should not be treated as interchangeable measures of anticancer drug response. Its framework helps researchers distinguish proliferative arrest from actual cell killing and design more interpretable in vitro experiments.
-
Acetylcysteine in 3D Tumor–Stroma Translation
2026-09-28
Acetylcysteine, also known as N-acetyl-L-cysteine, can serve as a controlled redox perturbation in patient-derived pancreatic cancer organoid–fibroblast models. This thought-leadership perspective connects glutathione biology, oxidative stress pathway modulation, and chemoresistance testing while defining practical controls, translational boundaries, and opportunities beyond conventional product-page descriptions.
-
LMO2–LDB1 Signaling in Acute Myeloid Leukemia
2026-09-28
The study identifies an LMO2–LDB1 protein complex in leukemia models and links LDB1 to AML-cell growth, survival, and regulation of apoptosis-related genes. Its combined perturbation, interaction, and sequencing evidence supports further investigation of this transcriptional axis, while leaving clinical relevance and the precise causal mechanisms to be established.
-
Engineering T-Cell Immunity in Immune-Cold Tumors
2026-09-27
He et al. report a tumor-directed plasmid strategy that combines LIGHT-mediated immune remodeling with anti-CD3-mediated T-cell engagement to address barriers in immune-cold solid tumors. In preclinical models, the approach enhanced antitumor immunity and improved responses to checkpoint blockade and CAR-T therapy, while its translation will require further validation of tumor selectivity, safety, and efficacy.
-
EZ Cap™ Firefly Luciferase mRNA for Assays
2026-09-26
Use a capped luciferase transcript to compare mRNA delivery, translation, and cell responses with a sensitive light-based readout. Practical workflows connect reporter assay design to emerging mRNA-stability research—without treating a research reagent as a pre-optimized nanoparticle formulation.
-
Dimetridazole Disarms P. aeruginosa Quorum Sensing
2026-09-25
Yuan et al. report that Dimetridazole and Ribavirin reduce quorum-sensing-associated virulence traits in Pseudomonas aeruginosa, including pyocyanin, protease production, and biofilm formation. By combining phenotypic assays, gene-expression analysis, antibiotic-combination tests, and infection models, the study frames these compounds as candidates for antivirulence research—not as established treatments for human infection.
-
A-769662 and the Energy Budget of Autophagy
2026-09-25
A-769662 is an AMPK activator for probing how energy stress reshapes metabolism and autophagy. This article connects AMPK pharmacology to recent evidence that the kinase can restrain autophagy initiation while preserving the machinery needed for recovery.
-
Firefly Luciferase mRNA: Assay Workflows
2026-09-24
Build a reproducible luminescence workflow around a capped, 5-methoxyuridine-modified reporter—and distinguish delivery failure from changes in cell health. Practical pilot conditions, troubleshooting guidance, and a carefully bounded connection to oral RNA nanoparticle research help teams choose the right next experiment.